Published in final edited form as:

Org Lett. 2011 May 6; 13(9): 2384–2387. doi:10.1021/ol200627d.

A Convergent Route to the CDEF Tetracycle of Pectenotoxin-2

Daniel P. Canterbury and Glenn C. Micalizio*

Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458

Abstract

— = C–C bonds forged in this convergent synthesis of the CDEF tetracycle.

A convergent synthesis of the CDEF tetracyclic region of pectenotoxin-2 (PTX-2) is described. The synthetic pathway derives from head-to-tail union of 2 equivalents of linalool to establish a stereodefined DEF tricyclic aldehyde. Subsequent coupling with a “northern” fragment enolate, followed by a tandem Sharpless epoxidation/cyclization delivers the C10–C26 polycyclic region of the natural product.

Actin is among the most abundant proteins in eukaryotic cells, and its ability to reversibly assemble into long and flexible filaments controls cell shape, movement, cell division, and adherens junctions between cells. The actin network also provides an essential scaffold for critical enzymes and signaling complexes, and is necessary for tumor cell migration, invasion, metastasis and tumor angiogenesis. Marine-derived natural products have defined a rich source of small molecules capable of destabilizing F-actin (i.e. reidispongiolide A, kabiramide C, scytophycin C, swinholide A, aplyronine A and bistramide).¹ Within this subset, the pectenotoxins represent a particularly novel class, both with regard to their exquisite molecular complexity and their mechanism of action.² The most potent of this class, pectenotoxin-2 (PTX-2; Figure 1), has recently been demonstrated to destabilize F-actin and be selectively cytotoxic to p53-mutant and p53(–) cancers.³ While demonstrating attractive anticancer properties, the development of these marine-derived natural products as potential therapeutics remains in its infancy due primarily to their low natural abundance. Here, we describe our initial foray into the chemistry of PTX-2 that has culminated in a convergent entry to the CDEF tetracyclic heterocycle.

To prioritize our efforts directed toward a chemical synthesis of PTX-2, we began with an analysis of its complex with G-actin (Figure 1B), and the limited structure-activity-relationships established for the pectenotoxin family.⁴ In short, the C and H rings play important roles in binding, while the AB spiroketal appears to serve as a scaffolding element to ensure proper orientation of these subunits. Not surprisingly, this role is significantly

micalizio@scripps.edu.

Supporting Information Available Experimental procedures and tabulated spectroscopic data for new compounds (PDF). This material is available free of charge via the Internet at <http://pubs.acs.org>.

affected by the C7 stereochemistry, with the C7(*R*) isomers demonstrating markedly enhanced activities.⁵ The oxidation state of C43 also plays an important role in modulating the cytotoxicity of the pectenotoxins – apparently, there exists insufficient molecular features on G-actin to accommodate higher oxidation states at C43.⁵ In sum, these structural studies provide insight into the roles that each region of the natural product play in binding to G-actin: The AB ring system and the 1,3-diene appear to play scaffolding roles to properly orient the CDEF- and GH-subunits for binding. Because of the central role that the CDEF tetracycle plays, and its presence in all known pectenotoxins, our initial chemical studies focused on this subunit.^{6, 7}

As highlighted in Scheme 1, the CDEF tetracyclic region of PTX-2 (**1**) is quite complex, and is composed of stereochemically distinct tetrahydrofurans, a central bridged bicyclic acetal, and three tertiary ethers. To date, a variety of approaches to this system have been reported that target embrace chemistry spanning hydrazone alkylation, carbonyl addition, Julia olefination, and aldol chemistry. Additionally, a strategy reported by Roush targeted convergent assembly of this subunit via annulation of the C- and F-rings about a central DE-ring precursor.^{7a}

We opted to pursue a strategy to tetracycle **2** that was distinct from these previously described approaches, embracing metal-mediated site- and stereoselective coupling of a suitably functionalized TMS-alkyne **3** with a tricyclic aldehyde **4**. Overall, reductive cross-coupling followed by stereoselective epoxidation and acid-catalyzed ring closure was targeted as a general convergent annulation strategy for union of a functionalized DEF-tricycle with the “northern” C1–C14 subunit. The requisite coupling partner **4** was then reasoned to be accessible by oxidative functionalization of **5**, itself derived from a head-to-tail dimerization of commercially available linalool in a fashion to forge the C20–C21 bond.

We prepared coupling partners **8** and **10** from linalool by a simple sequence of robust functional group manipulations. As depicted in Scheme 2A, vinyl iodide **8** was generated through a sequence of: 1) TES protection, 2) site-selective oxidative cleavage of the trisubstituted alkene,⁸ 3) alkynylation,⁹ and 4) hydrozirconation/iodination.¹⁰ As illustrated in Scheme 2B, a slightly different sequence of robust reactions were employed to access coupling partner **10**: 1) TBS protection, 2) site-selective oxidative cleavage of the trisubstituted alkene,⁸ 3) diastereoselective α -hydroxylation under the MacMillan/McQuade conditions (*dr* $\geq$ 20:1),¹¹ 4) reduction, and 5) acetonide formation.

As depicted in Scheme 3, the assembly of the tricyclic acetal **4** was accomplished by a simple six-step sequence. First, hydroboration/Suzuki coupling¹² defined a robust means of coupling the linalool derivatives **8** and **10**. After careful purification, Shi epoxidation¹³ of **5** provided **11** in 59% yield (*dr* $\geq$ 20:1). Desilylation with TBAF, followed by treatment with HCl in CHCl₃ resulted in cyclization to deliver the stereodefined tetrahydrofuran **12** in 86% yield. Finally, a simple three-step sequence was used to advance this intermediate to the functionalized aldehyde **4**: 1) oxidation to the ketone, 2) acid-promoted desilylation of the tertiary TBS ether with concomitant formation of the bicyclic acetal,¹⁴ and 3) oxidation to the C15 aldehyde.

With a robust route to the polycyclic acetal **4**, we turned our attention to the synthesis of a suitably functionalized enyne to be employed as a C-ring precursor. As illustrated in Scheme 4, we selected to employ a simple model for the “northern” fragment. Conversion of the readily available allylic alcohol **13** to the stereodefined allylic chloride **14** was possible by a two-step sequence consisting of nucleophilic addition of 2-propenylmagnesium bromide, followed by NbCl₅-mediated chlorination (*E:Z* $\geq$ 20:1),¹⁵ and coupling with TMS-acetylene (CuI, K₂CO₃, TBAI, CH₃CN).¹⁶

With ample precedent supporting the compatibility of functionalized enynes with Ti-mediated reductive cross-coupling chemistry,¹⁷ fragment assembly was pursued with Sato's regioselective TMS-alkyne–aldehyde reductive cross-coupling reaction.¹⁸ Unfortunately, all attempts to accomplish the Ti-mediated coupling between enyne **14** and aldehyde **4** led to complex product mixtures. While other procedures for reductive cross-coupling of alkynes with aldehydes are well-established,¹⁹ available methods typically do not deliver the regioisomeric product that was required in this PTX-2 synthesis campaign.

In the search for a suitable nucleophile to join a “northern” fragment of PTX-2 with the DEF-tricyclic aldehyde **4**, we turned our attention to well-established aldol chemistry.²⁰ As illustrated in Scheme 5, allylic alcohol **15**²¹ was converted to the stereodefined imide **16** by a straightforward three-step sequence: 1) Johnson ortho-ester Claisen rearrangement (*E:Z* ≥ 20:1), 2) saponification, and 3) imide formation. To our delight, Bu₂BOTf-mediated stereoselective aldol reaction between **16** and **4** proceeded with high levels of stereoselection (*dr* ≥ 20:1) and delivered, after desilylation (CAS, MeOH), the functionalized diol **17** in 73% yield. Subsequent Sharpless epoxidation²² led to a metastable intermediate that promptly cyclized *in situ* to furnish the stereodefined C-ring and the fully functionalized CDEF-tetracycle of PTX-2 (**18**) in 53% yield (*dr* ≥ 20:1).

In summary, we have defined a synthetic pathway to the CDEF tetracycle of pectenotoxin 2-**(1)**. The route is highly convergent and delivers the stereochemically dense C10–C26 heterocyclic core by the stepwise construction of two C–C bonds: 1) union of two simple linalool derivatives through forging the C20–C21 bond, and 2) appending the “northern” fragment by C14–C15 bond formation, and oxidative cyclization. Overall, the sequence proceeds in 16 linear steps from linalool (24 total steps) and requires only 11 chromatographic operations. Further, the strategic implication of employing linalool for the entire C15–C26 segment (**4**) that incorporates two stereodefined tertiary ethers, is significant and offers a facile means to gain access to this complex segment of the natural product.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Professor D. Tyler McQuade (Department of Chemistry, Florida State University) for helpful discussions regarding the catalytic asymmetric α -hydroxylation reaction employed, and for a sample of the relevant urea. We also thank Professor Yian Shi (Department of Chemistry, Colorado State University) for helpful discussions.

References

1. (a) Allingham JS, Klenchin VA, Rayment I. *Cell Mol Life Sci.* 2006; 63:2119–2134. [PubMed: 16909206] (b) Fenteany G, Zhu S. *Curr Top Med Chem.* 2003; 3:593–616. [PubMed: 12570855]
2. (a) Yasumoto T, Murate M, Oshima Y, Sano M, Matsumoto GK, Clardy J. *Tetrahedron.* 1985; 41:1019–1025. (b) Sasaki K, Wright JLC, Yasumoto T. *J Org Chem.* 1998; 63:2475–2480. [PubMed: 11672107]
3. (a) Chae HD, Choi TS, Kim BM, Hung JH, Bang YJ, Shin DY. *Oncogene.* 2005; 24:4813–4819. [PubMed: 15870701] (b) Shin DY, Kim GY, Kim ND, Jung JH, Kim SK, Hang HS, Choi YH. *Oncol Rep.* 2008; 19:517–526. [PubMed: 18202802]
4. (a) Allingham JS, Miles CO, Rayment I. *J Mol Bio.* 2007; 371:959–970. [PubMed: 17599353] (b) Allingham JS, Klenchin VA, Rayment I. *Cell Mol Life Sci.* 2006; 63:2119–2134. [PubMed: 16909206] (c) Espina B, Rubiolo JA. *FEBS.* 2008; 275:6082–6088.

5. (a) Espina B, Louzao MC, Ares IR, Fonfría EW, Vilarino N, Vieytes MR, Yasumoto T, Botana LM. *Chem Res Toxicol*. 2010; 23:504–515. [PubMed: 20085294] (b) Ares I, Louzao C, Espina B, Vieytes MR, Miles CO, Yasumoto T, Botana L. *Cell Physiol Biochem*. 2007; 19:283–292. [PubMed: 17495468] (c) see also ref. 4a.
6. For total syntheses of PTX-4 and PTX-8, see: (a) Evans DA, Rajapakse HA. *Angew Chem Int Ed*. 2002; 41:4569–4573. (b) Evans DA, Rajapakse HA, Stenkamp D. *Angew Chem Int Ed*. 2002; 41:4573–4576.
7. For partial synthesis, and studies toward the syntheses of the pectenotoxins, see: (a) Micalizio GC, Roush WR. *Org Lett*. 2001; 3:1949–1952. [PubMed: 11405752] (b) Paquette LA, Peng X, Bondar D. *Org Lett*. 2002; 4:937–940. [PubMed: 11893190] (c) Pihko PM, Aho JE. *Org Lett*. 2004; 6:3849–3852. [PubMed: 15469365] (d) Bondar D, Liu J, Müller T, Paquette LA. *Org Lett*. 2005; 7:1813–1816. [PubMed: 15844913] (e) Halim R, Brimble MA, Merten J. *Org Lett*. 2005; 7:2659–2662. [PubMed: 15957915] (f) Vellucci D, Rychnovsky SD. *Org Lett*. 2007; 9:711–714. [PubMed: 17286378] (g) O'Connor PD, Knight CK, Friedrich D, Peng X, Paquette LA. *J Org Chem*. 2007; 72:1747–1754. [PubMed: 17269830] (h) Lotesta SD, Hou Y, Williams LJ. *Org Lett*. 2007; 9:869–872. [PubMed: 17286409] (i) Heapy AM, Wagner TW, Brimble MM. *Synlett*. 2007:2359–2362. (j) Fujiwara K, Aki Y, Yamamoto F, Kawamura M, Kobayashi M, Okano A, Awakura D, Shiga S, Murai A, Kawai H, Suzuki T. *Tetrahedron Lett*. 2007; 48:4523–4527. (k) Kolakowski RV, Williams LJ. *Tetrahedron Lett*. 2007; 48:4761–4764. (l) Aho JE, Salomäki E, Rissanen K, Pihko PM. *Org Lett*. 2008; 10:4179–4182. [PubMed: 18763802] (m) Carley S, Brimble MA. *Org Lett*. 2009; 11:563–566. [PubMed: 19117488] (n) Joyasawal S, Lotesta SD, Akhmedov NG, Williams LJ. *Org Lett*. 2010; 12:988–991. [PubMed: 20121257]
8. (a) Cooke F, Roy G, Magnus P. *Organometallics*. 1982; 1:893–897. (b) Rosini G, Marotta E, Raimondi A, Righi P. *Tetrahedron Asymmetry*. 1991; 2:123–138.
9. Miwa K, Aoyama T, Shioiri T. *Synlett*. 1992; 2:107–108.
10. (a) Schwartz J, Labinger JA. *Angew Chem*. 1976; 88:402–409. (b) Negishi E, Takahashi T. *Synthesis*. 1988:1–19. (c) Wipf P, Jahn H. *Tetrahedron*. 1996; 52:12853–12910.
11. (a) Poe SL, Bogdan AR, Mason BP, Steinbacher JL, Opalka SM, McQuade DT. *J Org Chem*. 2009; 74:1574–1580. [PubMed: 19199658] (b) Brown SP, Brochu MP, Sinz CJ, MacMillan DWC. *J Am Chem Soc*. 2003; 125:10808–10809. [PubMed: 12952459] (c) Zhong G. *Angew Chem Int Ed*. 2003; 42:4247–4250.
12. Chemler SR, Trauner D, Danishefsky SJ. *Angew Chem Int Ed*. 2001; 40:4544–4568.
13. (a) Wang Z, Tu Y, Frohn M, Zhang J, Shi Y. *J Am Chem Soc*. 1997; 119:11224–11235. (b) Wong OA, Shi Y. *Chem Rev*. 2008; 108:3958–3987. [PubMed: 18590339] (c) Diffendal JM, Danheiser RL. *Org Synth*. 2009; 11:183–188.
14. While the yield of this step was moderate (59%), no evidence could be found for the formation of a regioisomeric acetal.
15. Ravikumar PC, Yao L, Fleming FF. *J Org Chem*. 2009; 74:7294–7299. [PubMed: 19739606]
16. Davies KA, Abel RC, Wulff JE. *J Org Chem*. 2009; 74:3997–4000. [PubMed: 19422268]
17. (a) Diez PS, Micalizio GC. *J Am Chem Soc*. 2010; 132:9576–9578. [PubMed: 20586460] (b) Macklin T, Micalizio GC. *Nature Chem*. 2010; 2:638–643. [PubMed: 20651725]
18. (a) Harada K, Urabe H, Sato F. *Tetrahedron Lett*. 1995; 36:3203–3206. (b) Yamashita K, Urabe H, Sato F. *Tetrahedron Lett*. 1997; 38:4619–4622. (c) Belardi JK, Micalizio GC. *Org Lett*. 2006; 8:2409–2412. [PubMed: 16706538]
19. (a) Oblinger E, Montgomery J. *J Am Chem Soc*. 1997; 119:9065–9066. (b) Huang WS, Chan J, Jamison TF. *Org Lett*. 2000; 2:4221–4223. [PubMed: 11150204] (c) Miller KM, Huang WS, Jamison TF. *J Am Chem Soc*. 2003; 125:3442–3443. [PubMed: 12643701] (d) Mahandru GM, Lium G, Montgomery J. *J Am Chem Soc*. 2004; 126:3698–3699. [PubMed: 15038707] (e) Sa-ei K, Montgomery J. *Org Lett*. 2006; 8:4441–4443. [PubMed: 16986920] (f) Chaulagain MR, Sormunen GJ, Montgomery J. *J Am Chem Soc*. 2007; 129:9568–9569. [PubMed: 17628066] For a recent example where regiochemistry can be tuned by the nature of ligands employed in Ni-catalyzed reductive coupling between alkynes and aldehydes, see: (g) Malik HA, Sormunen GJ, Montgomery J. *J Am Chem Soc*. 2010; 132:6304–6305. [PubMed: 20394367]
20. (a) Cintas P. *Synthesis*. 1992:248–257. (b) Fürstner A. *Chem Rev*. 1999; 99:991–1045. [PubMed: 11848998] (c) Wessjohann LA, Scheid G. *Synthesis*. 1999:1–36.

21. Evans DA, Bartoli J, Shih TL. *J Am Chem Soc.* 1981; 103:2127–2129.
22. Harada T, Kurokawa H, Kagamihara Y, Tanaka S, Inoue A, Oku A. *J Org Chem.* 1992; 57:1412–1421.
23. Katsuki T, Martin VS. *Org React.* 1996; 48:1–299.

Figure 1.
Introduction to the pectenotoxins.

C–C bonds targeted in approaches to the CDEF-tetracyclic region of the pectenotoxins:

Evans - 2002* (C19–C20)

Paquette - 2005 (C15–C16)

Williams - 2007 (C20–C21)

Pihko - 2008 (C16–C17)

Brimble - 2009 (C20–C21)

* only reported total synthesis of a pectenotoxin (PTX-4 and -8)

Scheme 1.
Synthetic strategy for a model CDEF tetracycle.

A. Synthesis of a C21-C26 fragment precursor: **B. Synthesis of a C15-C20 fragment precursor:** **Scheme 2.**

Preparation of linalool-derived coupling partners.

Scheme 3.
Convergent coupling *en route* to a DEF-tricycle.

Scheme 4.
Synthesis of C-ring fragment precursor.

Scheme 5.
Generation of a CDEF tetracycle.